Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for rimegepant - for acute migraine only as per guidance

  1. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA919

  2. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA906

  3. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    15 May 2024
    View recommendations

    Sections for TA973